Do analysts prefer EVGN or CARM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evogene 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Carisma Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate AMPE or CARM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ampio Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Carisma Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is AMPE or CARM more profitable?

Ampio Pharmaceuticals has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -254.28%. Company Net Margins Return on Equity Return on Assets Ampio Pharmaceuticals N/A N/A N/A Carisma Therapeutics -254.28% N/A -192.17%

Do analysts rate PTPI or CARM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Petros Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Carisma Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer CARM or VINC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Carisma Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Vincerx Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts prefer CARM or LYRA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Carisma Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Lyra Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is CARM or LYRA more profitable?

Carisma Therapeutics has a net margin of -254.28% compared to Lyra Therapeutics' net margin of -7,266.08%. Company Net Margins Return on Equity Return on Assets Carisma Therapeutics -254.28% N/A -192.17% Lyra Therapeutics -7,266.08% N/A -59.82%

Carisma Therapeutics (CARM) Competitors

$0.0012 0.00 (0.00%)

As of 08/26/2026 12:29 PM Eastern

Compare

CARM vs. EVGN, AMPE, PTPI, VINC, and LYRA

Should you buy Carisma Therapeutics stock or one of its competitors? Carisma Therapeutics's main competitors and comparable companies include Evogene (EVGN), Ampio Pharmaceuticals (AMPE), Petros Pharmaceuticals (PTPI), Vincerx Pharma (VINC), and Lyra Therapeutics (LYRA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Carisma Therapeutics compare to Evogene?

Evogene (NASDAQ:EVGN) and Carisma Therapeutics (NASDAQ:CARM) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, valuation, dividends, institutional ownership, media sentiment, profitability and risk.

Evogene has higher earnings, but lower revenue than Carisma Therapeutics. Evogene is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evogene	$3.85M	1.27	-$8.48M	-$0.91	N/A
Carisma Therapeutics	$10.77M	0.00	-$60.48M	$0.73	0.00

Carisma Therapeutics has a net margin of -254.28% compared to Evogene's net margin of -694.18%. Carisma Therapeutics' return on equity of 0.00% beat Evogene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evogene	-694.18%	-156.53%	-86.80%
Carisma Therapeutics	-254.28%	N/A	-192.17%

10.4% of Evogene shares are owned by institutional investors. Comparatively, 44.3% of Carisma Therapeutics shares are owned by institutional investors. 7.4% of Evogene shares are owned by insiders. Comparatively, 6.9% of Carisma Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Evogene has a beta of 1.4, meaning that its stock price is 40% more volatile than the broader market. Comparatively, Carisma Therapeutics has a beta of -9.09, meaning that its stock price is 1,009% less volatile than the broader market.

In the previous week, Evogene had 7 more articles in the media than Carisma Therapeutics. MarketBeat recorded 7 mentions for Evogene and 0 mentions for Carisma Therapeutics. Evogene's average media sentiment score of 0.17 beat Carisma Therapeutics' score of 0.00 indicating that Evogene is being referred to more favorably in the media.

Company	Overall Sentiment
Evogene	Neutral
Carisma Therapeutics	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evogene	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Carisma Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Evogene beats Carisma Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Carisma Therapeutics compare to Ampio Pharmaceuticals?

Ampio Pharmaceuticals (NYSE:AMPE) and Carisma Therapeutics (NASDAQ:CARM) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk, profitability and valuation.

Ampio Pharmaceuticals has a beta of 5.96, indicating that its share price is 496% more volatile than the broader market. Comparatively, Carisma Therapeutics has a beta of -9.09, indicating that its share price is 1,009% less volatile than the broader market.

Ampio Pharmaceuticals has higher earnings, but lower revenue than Carisma Therapeutics. Ampio Pharmaceuticals is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ampio Pharmaceuticals	N/A	N/A	-$8.63M	-$11.01	N/A
Carisma Therapeutics	$10.77M	0.00	-$60.48M	$0.73	0.00

Ampio Pharmaceuticals has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -254.28%.

Company	Net Margins	Return on Equity	Return on Assets
Ampio Pharmaceuticals	N/A	N/A	N/A
Carisma Therapeutics	-254.28%	N/A	-192.17%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ampio Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Carisma Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Ampio Pharmaceuticals' average media sentiment score of 0.00 equaled Carisma Therapeutics'average media sentiment score.

Company	Overall Sentiment
Ampio Pharmaceuticals	Neutral
Carisma Therapeutics	Neutral

5.7% of Ampio Pharmaceuticals shares are owned by institutional investors. Comparatively, 44.3% of Carisma Therapeutics shares are owned by institutional investors. 3.3% of Ampio Pharmaceuticals shares are owned by company insiders. Comparatively, 6.9% of Carisma Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Carisma Therapeutics beats Ampio Pharmaceuticals on 6 of the 10 factors compared between the two stocks.

How does Carisma Therapeutics compare to Petros Pharmaceuticals?

Petros Pharmaceuticals (NASDAQ:PTPI) and Carisma Therapeutics (NASDAQ:CARM) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, risk, institutional ownership, profitability and valuation.

Petros Pharmaceuticals has a beta of 1.88, indicating that its stock price is 88% more volatile than the broader market. Comparatively, Carisma Therapeutics has a beta of -9.09, indicating that its stock price is 1,009% less volatile than the broader market.

Petros Pharmaceuticals has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -254.28%. Carisma Therapeutics' return on equity of 0.00% beat Petros Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Petros Pharmaceuticals	N/A	-78.22%	-23.50%
Carisma Therapeutics	-254.28%	N/A	-192.17%

In the previous week, Petros Pharmaceuticals' average media sentiment score of 0.00 equaled Carisma Therapeutics'average media sentiment score.

Company	Overall Sentiment
Petros Pharmaceuticals	Neutral
Carisma Therapeutics	Neutral

12.3% of Petros Pharmaceuticals shares are owned by institutional investors. Comparatively, 44.3% of Carisma Therapeutics shares are owned by institutional investors. 12.3% of Petros Pharmaceuticals shares are owned by insiders. Comparatively, 6.9% of Carisma Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Petros Pharmaceuticals has higher earnings, but lower revenue than Carisma Therapeutics. Petros Pharmaceuticals is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Petros Pharmaceuticals	$5.11M	0.03	-$8.16M	-$0.36	N/A
Carisma Therapeutics	$10.77M	0.00	-$60.48M	$0.73	0.00

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Petros Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Carisma Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Petros Pharmaceuticals and Carisma Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does Carisma Therapeutics compare to Vincerx Pharma?

Carisma Therapeutics (NASDAQ:CARM) and Vincerx Pharma (NASDAQ:VINC) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, profitability, analyst recommendations, media sentiment, earnings and institutional ownership.

Carisma Therapeutics has a beta of -9.09, indicating that its share price is 1,009% less volatile than the broader market. Comparatively, Vincerx Pharma has a beta of 1.44, indicating that its share price is 44% more volatile than the broader market.

44.3% of Carisma Therapeutics shares are owned by institutional investors. Comparatively, 44.0% of Vincerx Pharma shares are owned by institutional investors. 6.9% of Carisma Therapeutics shares are owned by insiders. Comparatively, 15.6% of Vincerx Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Vincerx Pharma has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -254.28%. Carisma Therapeutics' return on equity of 0.00% beat Vincerx Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Carisma Therapeutics	-254.28%	N/A	-192.17%
Vincerx Pharma	N/A	-248.33%	-132.73%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Carisma Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Vincerx Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Carisma Therapeutics' average media sentiment score of 0.00 equaled Vincerx Pharma'saverage media sentiment score.

Company	Overall Sentiment
Carisma Therapeutics	Neutral
Vincerx Pharma	Neutral

Vincerx Pharma has lower revenue, but higher earnings than Carisma Therapeutics. Vincerx Pharma is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Carisma Therapeutics	$10.77M	0.00	-$60.48M	$0.73	0.00
Vincerx Pharma	N/A	N/A	-$40.16M	-$5.31	N/A

Summary

Carisma Therapeutics beats Vincerx Pharma on 6 of the 11 factors compared between the two stocks.

How does Carisma Therapeutics compare to Lyra Therapeutics?

Carisma Therapeutics (NASDAQ:CARM) and Lyra Therapeutics (OTCMKTS:LYRA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, institutional ownership, profitability, risk, earnings, analyst recommendations and valuation.

Lyra Therapeutics has lower revenue, but higher earnings than Carisma Therapeutics. Lyra Therapeutics is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Carisma Therapeutics	$10.77M	0.00	-$60.48M	$0.73	0.00
Lyra Therapeutics	$400K	1.11	-$28.92M	-$19.15	N/A

Carisma Therapeutics has a beta of -9.09, suggesting that its share price is 1,009% less volatile than the broader market. Comparatively, Lyra Therapeutics has a beta of 0.72, suggesting that its share price is 28% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Carisma Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Lyra Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Carisma Therapeutics has a net margin of -254.28% compared to Lyra Therapeutics' net margin of -7,266.08%.

Company	Net Margins	Return on Equity	Return on Assets
Carisma Therapeutics	-254.28%	N/A	-192.17%
Lyra Therapeutics	-7,266.08%	N/A	-59.82%

In the previous week, Carisma Therapeutics' average media sentiment score of 0.00 equaled Lyra Therapeutics'average media sentiment score.

Company	Overall Sentiment
Carisma Therapeutics	Neutral
Lyra Therapeutics	Neutral

44.3% of Carisma Therapeutics shares are owned by institutional investors. Comparatively, 95.6% of Lyra Therapeutics shares are owned by institutional investors. 6.9% of Carisma Therapeutics shares are owned by company insiders. Comparatively, 3.3% of Lyra Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Carisma Therapeutics and Lyra Therapeutics tied by winning 5 of the 10 factors compared between the two stocks.

Get Carisma Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CARM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CARM vs. The Competition

Export

Metric	Carisma Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$50K	$12.24B	$7.23B	$12.87B
Dividend Yield	N/A	2.61%	2.54%	11.02%
P/E Ratio	0.00	780.49	272.48	24.29
Price / Sales	0.00	791.27	608.54	79.97
Price / Cash	N/A	96.46	79.89	53.65
Price / Book	0.00	12.02	13.12	6.25
Net Income	-$60.48M	$2.82B	$3.47B	$348.11M
7 Day Performance	N/A	2.00%	2.05%	1.47%
1 Month Performance	N/A	5.81%	8.25%	4.70%
1 Year Performance	N/A	7.24%	26.26%	17.01%

Carisma Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CARM Carisma Therapeutics	0.271 of 5 stars	$0.00 flat	N/A	-99.5%	$50K	$10.77M	0.00	20	Gap Up
EVGN Evogene	1.1811 of 5 stars	$0.58 +4.0%	N/A	-58.5%	$4.88M	$1.84M	N/A	140	News Coverage Positive News Short Interest Increase
AMPE Ampio Pharmaceuticals	N/A	$0.18 flat	N/A	N/A	$208K	N/A	N/A	20
PTPI Petros Pharmaceuticals	N/A	$0.00 +3.7%	N/A	-86.1%	$87K	$5.11M	N/A	20	Gap Up
VINC Vincerx Pharma	N/A	$0.01 flat	N/A	-78.8%	$66K	N/A	N/A	60

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CARM) was last updated on 8/27/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Carisma Therapeutics (CARM) Competitors

CARM vs. EVGN, AMPE, PTPI, VINC, and LYRA

How does Carisma Therapeutics compare to Evogene?

Summary

How does Carisma Therapeutics compare to Ampio Pharmaceuticals?

Summary

How does Carisma Therapeutics compare to Petros Pharmaceuticals?

Summary

How does Carisma Therapeutics compare to Vincerx Pharma?

Summary

How does Carisma Therapeutics compare to Lyra Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CARM vs. The Competition

Carisma Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Carisma Therapeutics (CARM) Competitors

CARM vs. EVGN, AMPE, PTPI, VINC, and LYRA

How does Carisma Therapeutics compare to Evogene?

Which has stronger earnings & valuation, EVGN or CARM?

Is EVGN or CARM more profitable?

Do insiders & institutionals believe in EVGN or CARM?

Which has more volatility & risk, EVGN or CARM?

Does the media refer more to EVGN or CARM?

Do analysts prefer EVGN or CARM?

Summary

How does Carisma Therapeutics compare to Ampio Pharmaceuticals?

Which has more volatility & risk, AMPE or CARM?

Which has preferable valuation and earnings, AMPE or CARM?

Is AMPE or CARM more profitable?

Do analysts rate AMPE or CARM?

Does the media refer more to AMPE or CARM?

Do institutionals and insiders believe in AMPE or CARM?

Summary

How does Carisma Therapeutics compare to Petros Pharmaceuticals?

Which has more risk & volatility, PTPI or CARM?

Is PTPI or CARM more profitable?

Does the media prefer PTPI or CARM?

Do insiders & institutionals believe in PTPI or CARM?

Which has higher valuation & earnings, PTPI or CARM?

Do analysts rate PTPI or CARM?

Summary

How does Carisma Therapeutics compare to Vincerx Pharma?

Which has more risk & volatility, CARM or VINC?

Do insiders and institutionals hold more shares of CARM or VINC?

Is CARM or VINC more profitable?

Do analysts prefer CARM or VINC?

Does the media favor CARM or VINC?

Which has stronger valuation and earnings, CARM or VINC?

Summary

How does Carisma Therapeutics compare to Lyra Therapeutics?

Which has stronger earnings and valuation, CARM or LYRA?

Which has more risk and volatility, CARM or LYRA?

Do analysts prefer CARM or LYRA?

Is CARM or LYRA more profitable?

Does the media prefer CARM or LYRA?

Do institutionals and insiders believe in CARM or LYRA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CARM vs. The Competition

Carisma Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools